Brief: QuiapPEG Pharmaceuticals Holding Presents Positive Preclinical Results For QPG-1029
11/02/2020 10:31
Feb 11 (Reuters) - QuiaPEG Pharmaceuticals Holding AB
QUIA.TE :
* PRESENTS POSITIVE PRECLINICAL RESULTS FOR QPG-1029
* THE RESULTS MEAN THAT QUIAPEG CONTINUES THE DEVELOPMENT
PROGRAM
FOR QPG-1029
* RESULTS FROM PRECLINICAL STUDY SHOW FOR THE FIRST TIME
THAT
QPG-1029 CAN BE ABSORBED IN BLOOD CIRCULATION AFTER INJECTION
* AFTER EVALUATION OF TREATMENT EFFECT IN PROOF-OF-CONCEPT
STUDY
CO IS TO CONDUCT PHARMACOKINETIC STUDIES WITH REPEATED DOSING,
COMPLETE WITH TOXICOLOGY AND SAFETY STUDIES TO BE PERFORMED
BEFORE CLINICAL PROGRAM WILL START
* RESULTS FROM PRECLINICAL STUDY SHOW THAT THE DRUG
LIRAGLUTID IS
RELEASED IN BLOOD PLASMA AFTER BOTH INTRAVENOUS AND SUBCUTANEOUS
ADMINISTRATION
Source text for Eikon: ID:nWkr1p9Wv7
Further company coverage: QUIA.TE
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))